Anti-Human BCL-2 (124)- Dylight^® 650 (B128-GRP)

BCL-2 is a member of a protein family that regulates apoptosis, with some members inducing (proapoptotic) and others inhibiting (antiapoptotic) apoptosis 1. BCL-2 acts as an antiapoptotic protein that prevents apoptosis and promotes survival in response to many cell stresses and cytotoxic chemicals 2 via the mitochondria-mediated intrinsic apoptosis pathway 1. BCL-2 is also an important oncogene whose overexpression is common in hematological malignancies such as follicular lymphoma, chronic lymphocytic leukemia, mantle cell leukemia and Waldenström's macroglobulinemia 1 as well as breast cancer 3. As such, BCL-2 is a target for inhibition in cancer immunotherapy. Additionally, BCL-2 is involved in cardiac hypertrophy and has been suggested as a potential therapeutic target for clinical management 4. Clone 124 was generated by immunizing mice with a synthetic peptide corresponding to amino acids 41 to 54 (GAAPAPGIFSSQPG) of BCL-2 conjugated to thyroglobulin 5. Sera were screened on cryostat sections of human tonsil and on a follicular lymphoma with a known 14;18 translocation. Cell fusion and hybridoma lines were produced by conventional technology. 124 recognizes BCL-2 by Western blotting under both reducing and non-reducing conditions.